CoChat

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Open access
Keysar, Stephen B., Astling, David P., Anderson, Ryan T., Vogler, Brian W., Bowles, Daniel W., Morton, J. Jason, Paylor, Jeramiah J., Glogowska, Magdalena J., Le, Phuong N., Eagles-Soukup, Justin R., Kako, Severine L., Takimoto, Sarah M., Sehrt, Daniel B., Umpierrez, Adrian, Pittman, Morgan A., Macfadden, Sarah M., Helber, Ryan M., Peterson, Scott, Hausman, Diana F., Said, Sherif, Leem, Ted H., Goddard, Julie A., Arcaroli, John J., Messersmith, Wells A., Robinson, William A., Hirsch, Fred R., Varella-Garcia, Marileila, Raben, David, Wang, Xiao-Jing, Song, John I., Tan, Aik-Choon, Jimeno, Antonio · 2013 · Molecular Oncology
Cited by 156

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an in vivo model derived from patients reflecting the evolving HNSCC epidemiologic landscape, and use it to identify new therapies. Primary and relapsed tumors from HNSCC patients, both HPV+ and HPV−, were implanted on mice, giving rise to 25 strains. Resulting xenografts were characterized by detecting key mutations, measuring protein expression by IHC and gene expression/pathway analysis by mRNA‐sequencing. Drug efficacy studies were run with representative xenografts using the approved drug cetuximab as well as the new PI3K inhibitor PX‐866. Tumors maintained their original morphology, genetic profiles and drug susceptibilities through serial passaging. The genetic makeup of these tumors was consistent with known frequencies of TP53, PI3KCA, NOTCH1 and NOTCH2 mutations. Because the EGFR inhibitor cetuximab is a standard HNSCC therapy, we tested its efficacy and observed a wide spectrum of efficacy. Cetuximab‐resistant strains had higher PI3K/Akt pathway gene expression and protein activation than cetuximab‐sensitive strains. The PI3K inhibitor PX‐866 had anti‐tumor efficacy in HNSCC models with PIK3CA alterations. Finally, PI3K inhibition was effective in two cases with NOTCH1 inactivating mutations. In summary, we have developed an HNSCC model covering its clinical spectrum whose major genetic alterations and susceptibility to anticancer agents represent contemporary HNSCC. This model enables to prospectively test therapeutic‐oriented hypotheses leading to personalized medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2013.03.004

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Keysar, S. B., Astling, D. P., Anderson, R. T., Vogler, B. W., Bowles, D. W., Morton, J. J., Paylor, J. J., Glogowska, M. J., Le, P. N., Eagles-Soukup, J. R., Kako, S. L., Takimoto, S. M., Sehrt, D. B., Umpierrez, A., Pittman, M. A., Macfadden, S. M., Helber, R. M., Peterson, S., Hausman, D. F., Said, S., Leem, T. H., Goddard, J. A., Arcaroli, J. J., Messersmith, W. A., Robinson, W. A., Hirsch, F. R., Varella-Garcia, M., Raben, D., Wang, X.-J., Song, J. I., Tan, A.-C., & Jimeno, A.
Venue
Molecular Oncology
Publisher
Wiley
Published
2013-04-04
Volume
7
Issue
4
Pages
776-790
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2112189502
Cited by
156
References
6
FWCI
13.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.